Pet IL-6 Therapeutic Antibody Development

Creative Biolabs advances innovative therapeutic antibody programs designed specifically for companion animals. Our expertise in veterinary biotechnology includes the development of interleukin-6 (IL-6) targeted antibodies, a promising therapeutic approach for managing chronic inflammation, immune-mediated conditions, and cancer in dogs and cats. By offering an integrated pipeline that spans discovery, engineering, characterization, and preclinical evaluation, we help partners translate IL-6 biology into practical veterinary treatments. If you are considering antibody-based therapies targeting IL-6, our specialized team is ready to support your program with tailored scientific solutions.

Platforms in Therapeutic Antibody Discovery

We provide multiple discovery platforms to ensure a robust and species-specific therapeutic pipeline. Each platform can be applied independently or combined strategically to broaden antibody diversity and increase success rates. If you are evaluating which approach best supports your therapeutic goals, Creative Biolabs can design a tailored discovery strategy for your IL-6 program.

• Phage Display: Our proprietary antibody libraries allow rapid identification of diverse, high-affinity IL-6 binders. These libraries are optimized for canine and feline immune systems, supporting the development of species-relevant therapeutic candidates.
• Single-B Cell Sorting: By isolating IL-6-specific B cells from immunized animals, we generate naturally paired antibodies that retain native diversity and functionality. These candidates serve as excellent starting points for downstream optimization.
• Hybridoma Technology: This reliable platform delivers stable monoclonal antibodies that can be further engineered for improved therapeutic profiles, ensuring durability, safety, and efficacy in pets.

Comprehensive Antibody Development Services

Our end-to-end services support every stage of antibody development to ensure reliable outcomes. By integrating these services, Creative Biolabs ensures continuity from discovery to preclinical validation. If your pipeline requires characterization or advanced preclinical assessment, our experts can provide the solutions you need.

Antibody Characterization

We provide detailed assessments of affinity, specificity, stability, and bioactivity, confirming candidate quality and therapeutic relevance.

Antibody Engineering

Using advanced molecular techniques, we refine antibodies for enhanced potency, improved pharmacokinetics, and reduced immunogenicity in canine and feline models.

Preclinical Evaluation

Our in vitro and in vivo studies validate therapeutic efficacy, safety, and pharmacodynamics, supporting translational readiness.

Antibody Development

We deliver scalable expression, purification, and quality control processes to generate research- or preclinical-grade antibody material.

Discover How We Can Help - Request a Consultation

Why Focus on IL-6?

IL-6 is a multifunctional cytokine that regulates inflammation, immune responses, and hematopoiesis. In disease states, excessive IL-6 signaling contributes to autoimmune conditions, chronic inflammation, and tumor progression. In dogs, IL-6 has been implicated in arthritis, inflammatory bowel disease, and lymphoma, while in cats, it plays a role in chronic gingivostomatitis, systemic inflammation, and certain cancers. Because IL-6 dysregulation spans multiple organ systems and species, it represents a valuable therapeutic target for both canine and feline health. Antibody-based inhibition of IL-6 offers the potential to control chronic inflammation and improve quality of life in pets affected by these conditions.

Mechanism of Action

IL-6-targeting antibodies function by binding to circulating IL-6 or its receptor, preventing the activation of downstream JAK/STAT signaling pathways. This blockade interrupts the pro-inflammatory cascade responsible for immune dysregulation, reducing cytokine release, tissue damage, and systemic symptoms. By modulating the pathway at its source, IL-6 inhibition offers a more targeted therapeutic approach than broad immunosuppressants, potentially improving safety while delivering significant clinical benefits in companion animals with chronic inflammatory or neoplastic diseases.

Fig 1. Alignment of the amino acid sequence of the human and canine IL-6R.¹

Our Advantages

• Species-Specific Solutions: Proprietary canine and feline antibody libraries ensure discovery of candidates optimized for veterinary use.
• Integrated Development Pipeline: End-to-end services streamline progression from discovery to translational studies.
• Scientific Precision: Rigorous characterization and preclinical evaluation reduce risks and strengthen decision-making.
• Flexible Collaboration: We adapt project structures to client needs, from focused discovery to comprehensive development programs.

Partner with Creative Biolabs

The development of IL-6 therapeutic antibodies represents a promising pathway for addressing inflammatory and immune-mediated diseases in pets. Creative Biolabs is committed to helping innovators transform this potential into veterinary treatments that improve the lives of dogs and cats worldwide. Whether your program is at the discovery stage or preparing for preclinical evaluation, our team is ready to provide tailored support. Contact us today to discuss your IL-6 antibody development project and explore partnership opportunities that align with your goals.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Merbl, Yael et al. "Tocilizumab binds to canine IL-6 receptor and elicits in-vitro inhibitory biological response." Frontiers in veterinary science vol. 12 1645414. 3 Sep. 2025. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fvets.2025.1645414